Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
BUSINESS
Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
Novartis Pharma AG has filed for arbitration against Mitsubishi Tanabe Pharma with the International Chamber of Commerce (ICC) claiming that the company is not obligated to pay certain royalties on sales of the multiple sclerosis treatment fingolimod, the Japanese company…
To read the full story
Related Article
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
- Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
February 15, 2023
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
BUSINESS
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- ASKA, Susmed Initiate Clinical Study of PMS Therapeutic App
January 29, 2025
- PeptiDream/RayzeBio’s Peptide-Radionuclide Theranostic Enter Clinic
January 29, 2025
- GSK Files Depemokimab for Asthma and CRSwNP in Japan
January 29, 2025
- KalVista Files HAE Drug Sebetralstat in Japan
January 29, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…